MULTICENTER CLINICAL-TRIAL OF THROMBOLYTIC THERAPY IN 1406 PATIENTS WITH ACUTE MYOCARDIAL-INFARCTION

Objective To investigate the clinical efficacy and safety of intraveno us thrombolytic therapy of Urokinase Tech-Pool (UKTP) in acute myocard ial infarction (AMI). Methods The data were collected from the 148 par ticipating hospitals from November, 1994 to April, 1996. A total of 14 06 patients with AMT were analyzed to evaluate the clinical efficacy, side effects and mortality of UKTP. The patency of the infarct-related artery (IRA) was evaluated in 124 patients by coronary artery angiogr aphy (CAG) 90 minutes after the onset of UKTP infusion. Results The re perfusion rate in IRA was 73. 5% by clinical standards. The patency ra te was 72. 6% by CAG. The total mortality during the first 5 weeks was 7. 8% (109/1406). The rate of minor bleeding was 10. 2% (143/1406), o f major bleeding 0. 43% (6/1406) and of intracranial hemorrhage 0. 50% (7/1406). In elderly patients (> 75 years old), UKTP was as effective and safe as in younger patients (< 65 years old). Late thrombolytic t herapy with UKTP (> 6 hours after the onset of symptom) was still effe ctive. The appropriate dosage of UKTP might be 150 million units of in fusion within 30 minutes. Conclusion UKTP is an effective, reliable an d safe agent in the thrombolytic therapy of AMI.